. Author manuscript; available in PMC: 2008 Apr 30.

Published in final edited form as: Hum Immunol. 2007 Mar 12;68(5):309–323. doi: 10.1016/j.humimm.2007.01.019

Table 2.

Matching of recipient HLA class I ligands to donor inhibitory KIR.

	All donor- recipient pairs (n=202)	AML/MDS donor- recipient pairs (n=78)
	N %	N %

Recipient has all ligands for Donor inhibitory KIR	16 (8)	6 (8)
Recipient A3 or 11⁻ / Donor 3DL2+	44 (22)	19 (24.5)
Recipient Bw4⁻ / Donor 3DL1⁺	10 (5)	4 (5)
Recipient C1⁻ / Donor 2DL2/3⁺	5 (2)	1 (1.25)
Recipient C2⁻ / Donor 2DL1⁺	16 (8)	8 (10)
Recipient A3/11⁻ and Bw4⁻ / Donor 3DL2⁺ and 3DL1⁺	18 (9)	5 (6.5)
Recipient A3/11⁻ and C1⁻ / Donor 3DL2⁺ and 2DL2/3⁺	16 (8)	5 (6.5)
Recipient A3/11⁻ and C2⁻ / Donor 3DL2⁺ and 2DL1⁺	26 (13)	14 (18)
Recipient Bw4⁻ and C1⁻ / Donor 3DL1⁺ and 2DL2/3⁺	0 (0)	0 (0)
Recipient Bw4⁻ and C2⁻ / Donor 3DL1⁺ and 2DL1⁺	13 (6)	4 (5)
Recipient A3/11^−- and Bw4⁻ and C1⁻ / Donor 3DL2⁺ and 3DL1⁺ and 2DL2/3⁺	8 (4)	1 (1.25)
Recipient A3/11⁻ and Bw4⁻ and C2⁻ / Donor 3DL2⁺ and 3DL1⁺ and 2DL2/3⁺	30 (15)	11 (14)